CD4 and chronic myelogenous leukemia, BCR-ABL1 positive: Recent experiments by Chen et al., observe that some CML patients under imatinib-induced remission develop a robust but transient anti-leukemia immune response involving both CD4+ and CD8+ T cells [8].